Abstract:Background: Mutations in low-density lipoprotein (LDL) receptor (LDLR) are one of the main causes of familial hypercholesterolemia, which induces atherosclerosis and has a high lifetime risk of cardiovascular disease. The clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system is an effective tool for gene editing to correct gene mutations and thus to ameliorate disease. Methods: The goal of this work was to determine whether in vivo somatic cell gene editing through the CRISPR/Cas9 system delivered by adeno-associated virus (AAV) could treat familial hypercholesterolemia caused by the Ldlr mutant in a mouse model. We generated a nonsense point mutation mouse line, Ldlr(E208X), based on a relevant familial hypercholesterolemia-related gene mutation. The AAV-CRISPR/Cas9 was designed to correct the point mutation in the Ldlr gene in hepatocytes and was delivered subcutaneously into Ldlr(E208X) mice. Results: We found that homogeneous Ldlr(E208X) mice (n=6) exhibited severe atherosclerotic phenotypes after a high-fat diet regimen and that the Ldlr mutation was corrected in a subset of hepatocytes after AAV-CRISPR/Cas9 treatment, with LDLR protein expression partially restored (n=6). Compared with the control groups (n=6 each group), the AAV-CRISPR/Cas9 with targeted single guide RNA group (n=6) had significant reductions in total cholesterol, total triglycerides, and LDL cholesterol in the serum, whereas the aorta had smaller atherosclerotic plaques and a lower degree of macrophage infiltration. Conclusions: Our work shows that in vivo AAV-CRISPR/Cas9-mediated Ldlr gene correction can partially rescue LDLR expression and effectively ameliorate atherosclerosis phenotypes in Ldlr mutants, providing a potential therapeutic approach for the treatment of patients with familial hypercholesterolemia.

The Thinking of Gene Therapy for Familial Hypercholesterolemia

Recent progress in gene therapy for familial hypercholesterolemia treatment

Novel Approaches for the Treatment of Familial Hypercholesterolemia: Current Status and Future Challenges.

Familial Hypercholesterolemia: Current Limitations and Future Breakthroughs

Recent Advances in Gene Therapy for Familial Hypercholesterolemia: An Update Review

Gene Sequencing Research of Three Familial Hypercholesterolemia Families

In Vivo AAV-CRISPR/Cas9–Mediated Gene Editing Ameliorates Atherosclerosis in Familial Hypercholesterolemia

Research Progress in Heritable Dyslipidemia

Review of the scientific evolution of gene therapy for the treatment of homozygous familial hypercholesterolaemia: past, present and future perspectives

Research Progress in the Clinical Treatment of Familial Hypercholesterolemia

Advances in familial hypercholesterolemia

Established and Emerging Nucleic Acid Therapies for Familial Hypercholesterolemia

[Advances in Diagnosis and Treatment of Familial Hypercholesterolemia].

Gene Therapy: Regulations, Ethics and Its Practicalities in Liver Disease

Advance in Gene Therapy of Tumors

Hemophilia Gene Therapy: from Bench to Bed Side.

Hemophilia Gene Therapy: New Development from Bench to Bed Side.

Familial Hypercholesterolemia and Atherosclerosis: Animal Models and Therapeutic Advances.

Regulatory Non-Coding RNAs in Familial Hypercholesterolemia, Theranostic Applications

Progress in studies of gene therapy for Huntington's disease

Gene Therapy:the Present and Prospect